Eltrombopag

(Promacta®)

Promacta®

Drug updated on 10/27/2023

Dosage FormTablet (oral; 12.5 mg, 25 mg, 50 mg, and 75 mg) Oral suspension (oral; 12.5 mg, 25 mg)
Drug ClassThrombopoietin receptor agonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
  • For the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. PROMACTA should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.
  • Indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.
  • For the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Promacta (eltrombopag) Prescribing Information.2023Novartis Pharmaceuticals Corporation East Hanover, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Eltrombopag for adults and children with immune-refractory thrombocytopenic purpura: a systematic review.2023Journal of Clinical Medicine
The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review.2023Frontiers in Pediatrics
Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: a systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials.2023Experimental and Therapeutic Medicine
Eltrombopag effectiveness and tolerability in chronic immune thrombocytopenia: a meta-analysis.2021Clinical and Applied Thrombosis/Hemostasis
Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review.2021Expert Review of Hematology
Safety and efficacy of eltrombopag and romiplostim in myelodysplastic syndromes: a systematic review and meta-analysis.2020Frontiers in Oncology
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis2019British Journal of Haematology
Therapeutic options for adult patients with previously treated immune thrombocytopenia – a systematic review and network meta-analysis.2019Hematology
Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.2018PLOS ONE
Efficacy and safety of eltrombopag for aplastic anemia: a systematic review and meta-analysis.2018Clinical Drug Investigation

Clinical Practice Guidelines